Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
Christine Dugovic, Jonathan Shelton, Sujin Yun, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Sleep in posttraumatic stress disorder: A systematic review and meta-analysis of polysomnographic findings
Ye Zhang, Rong Ren, Larry D. Sanford, et al.
Sleep Medicine Reviews (2019) Vol. 48, pp. 101210-101210
Closed Access | Times Cited: 100
A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics
Kayla Janto, J. Roxanne Prichard, Snigdha Pusalavidyasagar
Journal of Clinical Sleep Medicine (2018) Vol. 14, Iss. 08, pp. 1399-1408
Open Access | Times Cited: 81
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
Anthony L. Gotter, Mark S. Forman, C. Meacham Harrell, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 72
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Pascal Bonaventure, Jonathan Shelton, Sujin Yun, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 354, Iss. 3, pp. 471-482
Open Access | Times Cited: 71
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Open Access | Times Cited: 65
Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases
Alain Couvineau, Thierry Voisin, Pascal Nicole, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 63
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 56
OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2-INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES
Philip L. Johnson, Lauren M. Federici, Stephanie D. Fitz, et al.
Depression and Anxiety (2015) Vol. 32, Iss. 9, pp. 671-683
Open Access | Times Cited: 62
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep
Zachary D. Brodnik, David L. Bernstein, Courtney D. Prince, et al.
Behavioural Brain Research (2015) Vol. 291, pp. 377-384
Open Access | Times Cited: 46
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Peter de Boer, Wayne C. Drevets, Hany Rofael, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 6, pp. 668-677
Closed Access | Times Cited: 45
Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit
Shingo Soya, Takeshi Sakurai
Brain Research (2018) Vol. 1731, pp. 146037-146037
Open Access | Times Cited: 44
The EEG as an index of neuromodulator balance in memory and mental illness
Costa Vakalopoulos
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top